RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Reports Third Quarter 2021 Financial Results
November 10, 2021 16:05 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors
November 09, 2021 16:01 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics to Participate in Upcoming Investor Conferences
November 08, 2021 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,...
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit
October 18, 2021 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress
September 30, 2021 09:15 ET
|
RAPT Therapeutics, Inc.
Benefit demonstrated in all key exploratory efficacy endpoints - EASI, EASI-50, EASI-75, EASI-90, vIGA, BSA and pruritus NRS-3 and 4 - with once-daily, oral treatment with RPT193Continued improvement...
RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress
September 20, 2021 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,...
RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference
September 20, 2021 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,...
RAPT Therapeutics to Present at Upcoming Investor Conferences
September 03, 2021 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering,...
RAPT Therapeutics Reports Second Quarter 2021 Financial Results
August 11, 2021 08:00 ET
|
RAPT Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing...